Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01218100 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
A Phase 4 study of Stage 2 Diastolic Hypertension, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 664
- Enrollment target
- 20
- Study locations
NCT01218100 is a Phase 4 study of Stage 2 Diastolic Hypertension that has completed, run by Forest Laboratories. The registered enrollment target is 664 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT01218100, a Phase 4 study of Stage 2 Diastolic Hypertension, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 664 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of first-line treatment with a free combination (as two separate pills) of nebivolol and lisinopril in patients with stage 2 diastolic hypertension (DBP\>= 100 mmHg).
Conditions Studied
Interventions
- DRUG placebo
- DRUG nebivolol and lisinopril (free combination)
- DRUG nebivolol monotherapy
- DRUG lisinopril monotherapy
Study Locations (20)
California
- Forest Investigative site 038 - Buena Park
- Forest Investigative site 075 - Burbank
- Forest Investigative site 042 - Costa Mesa
- Forest Investigative site 028 - Fountain Valley
- Forest Investigative site 064 - Fresno
- Forest Investigative site 079 - Lancaster
- Forest Investigative site 097 - Long Beach
- Forest Investigative site 049 - Los Angeles
- Forest Investigative site 081 - Riverside
- Forest Investigative site 040 - San Marino
- Forest Investigative site 059 - San Ramon
- Forest Investigative site 074 - Santa Ana
- Forest Investigative site 072 - Tustin
Arizona
- Forest Investigative Site #58 - Scottsdale
- Forest Investigative site 080 - Tempe
- Forest Investigative site 096 - Tucson
Florida
- Forest Investigative site 019 - Boca Raton
- Forest Investigative site 056 - Brandon
Colorado
- Forest Investigative site 077 - Colorado Springs
Connecticut
- Forest Investigative site 050 - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 664 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01218100
The ClinicalTrials.gov registry entry for NCT01218100 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 664 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage 2 Diastolic Hypertension appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.
NCT01218100 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT01218100 about?
NCT01218100 is a clinical study titled "Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension". This study will evaluate the safety and efficacy of first-line treatment with a free combination (as two separate pills) of nebivolol and lisinopril in patients with stage 2 diastolic hypertension (DBP\>= 100 mmHg).
What is the current status of trial NCT01218100?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 664 participants. The study started on 2010-10. Estimated completion is 2011-06.
What conditions does trial NCT01218100 study?
This clinical trial studies the following conditions: Stage 2 Diastolic Hypertension.
What interventions are being tested in trial NCT01218100?
The interventions under investigation include: placebo (DRUG), nebivolol and lisinopril (free combination) (DRUG), nebivolol monotherapy (DRUG), lisinopril monotherapy (DRUG).
Who is sponsoring clinical trial NCT01218100?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01218100 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.